NASDAQ:CMMB Chemomab Therapeutics (CMMB) Stock Price, News & Analysis $1.77 +0.03 (+1.72%) Closing price 04:00 PM EasternExtended Trading$1.77 0.00 (0.00%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Chemomab Therapeutics Stock (NASDAQ:CMMB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Chemomab Therapeutics alerts:Sign Up Key Stats Today's Range$1.71▼$1.8150-Day Range$1.44▼$2.1452-Week Range$1.35▼$5.88Volume32,608 shsAverage Volume38,162 shsMarket Capitalization$12.73 millionP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingHold Company Overview Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development. Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes. Its lead oncology programs employ novel bispecific formats intended to engage immune effector cells against solid tumors, while infectious disease programs focus on broad-spectrum neutralization of viral pathogens. Chemomab’s inflammatory disease efforts seek to modulate autoimmune pathways through highly selective receptor blockade. Headquartered in Shanghai with a presence in the United States, Chemomab fosters global collaboration with academic institutions and contract research organizations. The company was founded by a team of immunology and protein engineering experts and is led by a management group with extensive experience in biotechnology R&D and regulatory affairs. Through strategic partnerships and disciplined clinical development, Chemomab Therapeutics is positioning itself to address significant unmet medical needs in multiple therapeutic areas.AI Generated. May Contain Errors. Read More Chemomab Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreCMMB MarketRank™: Chemomab Therapeutics scored higher than 30% of companies evaluated by MarketBeat, and ranked 649th out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingChemomab Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialChemomab Therapeutics has a consensus price target of $25.00, representing about 1,312.4% upside from its current price of $1.77.Amount of Analyst CoverageChemomab Therapeutics has received no research coverage in the past 90 days.Read more about Chemomab Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Chemomab Therapeutics are expected to decrease in the coming year, from ($0.40) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chemomab Therapeutics is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chemomab Therapeutics is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChemomab Therapeutics has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Chemomab Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.79% of the float of Chemomab Therapeutics has been sold short.Short Interest Ratio / Days to CoverChemomab Therapeutics has a short interest ratio ("days to cover") of 1.39, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chemomab Therapeutics has recently increased by 6.02%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldChemomab Therapeutics does not currently pay a dividend.Dividend GrowthChemomab Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Chemomab Therapeutics this week, compared to 1 article on an average week. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Chemomab Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.91% of the stock of Chemomab Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.05% of the stock of Chemomab Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Chemomab Therapeutics' insider trading history. Receive CMMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMMB Stock News HeadlinesChemomab Therapeutics Ltd ADR CMMBMay 8 at 5:30 PM | morningstar.comMChemomab Therapeutics - Depositary Receipt (CMMB) price target decreased by 14.29% to 15.30March 28, 2026 | msn.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.May 8 at 1:00 AM | American Alternative (Ad)Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate UpdateMarch 19, 2026 | globenewswire.comChemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 17, 2026 | globenewswire.comChemomab Therapeutics - depositary receipt (CMMB) price target decreased by 33.96% to 17.85February 4, 2026 | msn.comMaxim Group Keeps Their Buy Rating on Chemomab Therapeutics (CMMB)December 25, 2025 | theglobeandmail.comChemomab Therapeutics announces results of its Phase 2 SPRING trialDecember 2, 2025 | msn.comSee More Headlines CMMB Stock Analysis - Frequently Asked Questions How have CMMB shares performed this year? Chemomab Therapeutics' stock was trading at $1.65 on January 1st, 2026. Since then, CMMB stock has increased by 7.3% and is now trading at $1.77. How were Chemomab Therapeutics' earnings last quarter? Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) announced its earnings results on Thursday, March, 19th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.04. When did Chemomab Therapeutics' stock split? Chemomab Therapeutics's stock reverse split before market open on Tuesday, August 26th 2025.A 1-4 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. When did Chemomab Therapeutics IPO? Chemomab Therapeutics (CMMB) raised $31 million in an initial public offering on Tuesday, February 12th 2019. The company issued 2,652,174 shares at a price of $11.50 per share. Who are Chemomab Therapeutics' major shareholders? Chemomab Therapeutics' top institutional investors include Kestra Private Wealth Services LLC (0.86%). View institutional ownership trends. How do I buy shares of Chemomab Therapeutics? Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Chemomab Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Chemomab Therapeutics investors own include Arista Networks (ANET), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW), NVIDIA (NVDA), Meta Platforms (META) and Adobe (ADBE). Company Calendar Last Earnings3/19/2026Today5/08/2026Next Earnings (Estimated)5/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CMMB's financial health is in the Red zone, according to TradeSmith. CMMB has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMMB CIK1534248 Webwww.chemomab.com Phone972-77-331-0156FaxN/AEmployees20Year Founded2010Price Target and Rating Average Price Target for Chemomab Therapeutics$25.00 High Price Target$25.00 Low Price Target$25.00 Potential Upside/Downside+1,312.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($2.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.99 million Net MarginsN/A Pretax MarginN/A Return on Equity-103.85% Return on Assets-90.44% Debt Debt-to-Equity RatioN/A Current Ratio9.08 Quick Ratio9.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.00 per share Price / Book0.89Miscellaneous Outstanding Shares7,192,000Free Float6,335,000Market Cap$12.73 million OptionableNot Optionable Beta0.51 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:CMMB) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | SponsoredBatten down the hatches – Project Tengu is comingStarting June 16, This AI Lab Could Take Off Dramatically Time magazine recently named this lab "the most d...Chaikin Analytics | SponsoredNobody's Asking Where The SpaceX Money Comes FromWhen SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...Americas Gold Company | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
